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Abstract
Introduction: Following trauma, patients may suffer an overwhelming pro-inflammatory response and immune
paralysis resulting in infection and multiple organ failure (MOF). Various potentially immunomodulative
interventions have been tested. The objective of this study is to systematically review the randomized controlled
trials (RCTs) that investigate the effect of potentially immunomodulative interventions in comparison to a placebo
or standard therapy on infection, MOF, and mortality in trauma patients.
Methods: A computerized search of MEDLINE, the Cochrane CENTRAL Register of Controlled Trials, and EMBASE
yielded 502 studies, of which 18 unique RCTs were deemed relevant for this study. The methodological quality of
these RCTs was assessed using a critical appraisal checklist for therapy articles from the Centre for Evidence Based
Medicine. The effects of the test interventions on infection, MOF, and mortality rates and inflammatory parameters
relative to the controls were recorded.
Results: In most studies, the inflammatory parameters differed significantly between the test and control groups.
However, significant changes in infection, MOF, and mortality rates were only measured in studies testing
immunoglobulin, IFN-g, and glucan.
Conclusions: Based on level 1b and 2b studies, administration of immunoglobulin, IFN-g, or glucan have shown
the most promising results to improve the outcome of trauma patients.
Introduction
Trauma remains the leading cause of death in people
under the age of 40 years [1], with multiple organ failure
(MOF) accounting for 27.5% of deaths among trauma
patients [2]. MOF can be a result of an early over-reac-
tion of the immune system or a late immune paralysis
[3]. Several groups have reviewed the changes that
occur in the immune system as a result of injury and
concluded that pro- and anti-inflammatory reactions
play a role in the development of MOF [4-7]. Early
MOF, which develops within the first three days after
injury without signs of infection, is attributed to an
overwhelming leukocyte driven pro-inflammatory
response clinically defined as a systemic inflammatory
response syndrome (SIRS). Late MOF, on the other
hand, is most often associated with infection and occurs
more than three days after injury. Late MOF seems to
be the result an inadequate specific immune response
with diminished antigen presentation, referred to as
compensatory anti-inflammatory response syndrome
(CARS). Many argue that SIRS and CARS occur simul-
taneously as a mixed antagoni s t i cr e s p o n s es y n d r o m e
(MARS) [4,6] and therefore both reactions contribute to
the occurrence of infection, sepsis, and MOF.
This knowledge needs to be applied. Which interven-
tions attenuate both the hyper-inflammatory response and
immune paralysis and subsequently improve the clinical
outcome in trauma patients? Montejo et al. [8] have sys-
tematically reviewed the effect of immunonutrition on
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nutrition shortened the time of mechanical ventilation and
ICU stay, and resulted in a lower incidence of bacteremias
and intra-abdominal infections, the incidence of nosoco-
mial pneumonia, wound infection, urinary tract infection,
sepsis, and mortality remain unchanged. Other interven-
tions are needed.
The objective of this paper is to systematically review
the randomized controlled trials (RCTs) that investigate
the effect of non-nutritional potential immunomodula-
tive interventions in comparison to a placebo or stan-
dard therapy on infection, MOF, and mortality in
trauma patients.
Materials and methods
Search
Studies were found via computerized searches of the
MEDLINE and EMBASE databases and the Cochrane
CENTRAL Register of Controlled Trials. The search
syntax included synonyms of trauma (trauma*, injur*),
immunomodulation (immun*, inflammat*), and clinical
outcome (infectio*, “organ failure”, mortality, surviv*) in
the titles, abstracts, and keywords areas. Limits were set
to retrieve only studies on humans with high-quality
design (meta-analyses, systematic reviews, Cochrane
reviews, RCTs, and clinical trials). No limits were
imposed on either publication date or language.
Selection
The search hits were screened for relevance by two
authors. Studies were deemed relevant when they inves-
tigated the effect of a potentially immunomodulative
intervention on clinical outcome in trauma patients.
Therefore, studies including patients other than trauma
patients (for example, other ICU patients), patients with
specific isolated injury (for example, isolated injury to
the head or an extremity), or patients with thermal inju-
ries were excluded. Furthermore, patients needed to be
randomly allocated to receive a potentially immunomo-
dulative intervention, standard therapy, or a placebo. As
the effect of immunonutrition has already been systema-
tically reviewed, studies implementing immunonutrition
were excluded. To assess the efficacy of the interven-
tions, only studies reporting clinical outcomes were
included. References of the relevant studies were
checked for other relevant articles that might have been
missed in the computerized search.
Quality assessment
The methodological quality of each of the studies for
which the full text was available was assessed using a
checklist for therapy articles from the Centre for Evi-
dence Based Medicine [9,10]. One point was accredited
for each positive criterion: the study participants were
randomized; the study groups had similar characteristics
at baseline; the groups were treated equally except for
the test intervention; all patients were accounted for;
outcome assessors were blinded to the intervention or
used well-defined outcome criteria; and outcomes were
compared on an intention-to-treat basis.
Data abstraction
Data abstraction was completed independently. The stu-
dies were searched for patient characteristics (number,
age, and injury severity score (ISS)), details of the inter-
vention (test, control, delivery route, and duration) and
length of follow-up during which outcome variables
were measured. Outcome variables included in the ana-
lysis were: infections, overall or specified; MOF or mor-
tality; and inflammatory parameters, cellular or humoral.
Definitions of infections given by authors were used,
including major and minor infections, pneumonia, sep-
sis, meningitis, surgical site infections, urinary tract
infections, and intra-abdominal abscesses. MOF was
defined by MOF scores given by the authors. The effi-
cacy of interventions intended to attenuate the hyper-
inflammatory response were compared with those
intended to reduce the immune paralysis. Interventions
that altered the release of pro-inflammatory cytokines
(IL-1b,I L - 6 ,I L - 8 ,T N F - a), active complement factors,
leukocyte count, or leukocyte-derived cytotoxic media-
tors were considered modulators of SIRS. Interventions
that altered the release of anti-inflammatory cytokines
(IL-10, IL-1RA), antigen-presenting capacity, or bacteri-
cidal capacity were considered modulators of CARS.
Results
Search and selection
After filtering out duplicate studies retrieved from the
databases, 502 potentially relevant studies were assessed.
Studies were excluded that did not include only trauma
patients (444), tested interventions that were not
intended to immunomodulate (10), studied the effect of
immunonutrition (20), did not report clinical outcome
(4), or were non-systematic reviews (5) (Figure 1). The
full text was not available for two studies [11,12]. By
checking references of the relevant studies, three other
relevant studies were found that were missed in the
computerized search because the keywords were not
included in the titles or abstracts [13-15]. Two articles
by Seekamp et al. [16,17] and two articles by Dries et al.
[13,18] report on the same study. Therefore, 18 unique
RCTs that met the inclusion and exclusion criteria were
available for analysis.
Quality assessment
Using the checklist for therapy articles from the Centre
for Evidence Based Medicine [9], all RCTs scored four
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were lost because the study groups were dissimilar at
baseline and/or patients dropped out that were not ana-
lyzed on an intention-to-treat basis. Studies scoring a
full six points were deemed high-quality RCTs reporting
1b level of evidence [10]. Studies scoring four or five
points were deemed of lesser quality and thus reporting
2b level of evidence. Data from all studies were used to
determine the effect of potential immunomodulative
interventions on clinical outcome in trauma patients.
Study characteristics
A comparison of the study characteristics of the 18
RCTs reveals marked inter-trial heterogeneity of patients
and interventions (Table 2). The number of patients
included in the trials ranged from 16 to 268, with five
trials studying over 100 patients [19-23]. Of the smaller
trials, six were pilot studies [14,24-27]. Three of the
trials were phase II trials primarily powered to test
dosage and safety, not efficacy [16,23,24]. Patient ages
ranged between 13 and 90 years, with the mean age in
the 30 s or low 40 s for all studies except those of Rizoli
et al. [27] and Seekamp et al. [16,17] in which the mean
age was nearer 50 years. Similarly, the ISS ranged from
0 to 75, with the mean ISS in the 20 s or low 30 s for
most studies. The studies by Nakos et al. [26] and
Waydhas et al. [28] averaged more severely injured
patients.
Interventions were intended to attenuate the early
overwhelming inflammatory response and diminish the
immune paralysis. As many trauma patients are plagued
by infections, researchers aimed to augment the host’s
inflammatory response by stimulating macrophages with
glucan [29,30], activating monocytes with dextran [14],
upregulating human leukocyte antigen (HLA)-DR
expression with interferon (IFN)-g [18,22,26,31], and
providing immunoglobulins [20,32]. As hyper-inflamma-
tion causes injury, researchers aimed to taper the host’s
inflammatory response by infusing leuko-reduced blood
[21], prostaglandin E1 [15], antioxidants [25], and
antithrombin III [28], which, by blocking thrombin,
decreases IL-8 production and sequestration of
Figure 1 Study selection. Computerized search conducted on 4 January, 2010.
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binds to endothelium (CD18) [23] or an adhesion mole-
cule (L-selectin) [16] with an antibody, researchers
hoped to prevent neutrophils from extravasating and
causing reperfusion injury after hemorrhagic shock. Per-
flubron is attributed with anti-inflammatory properties
because macrophages exposed to it demonstrate signifi-
cantly less hydrogen peroxide superoxide anion and pro-
duction [24]. Most of the control groups were given a
placebo [15-18,20,22,23,25-32] and four received only
standard treatment [14,19,21,24]. The interventions were
administered intravenously [14-17,19-21,23,25,27-30,32],
subcutaneously [18,22,31], or via inhalation [24,26].
Interventions were initiated as soon as possible after
injury by ambulance personnel [19] or as late as
145 hours after hospital admission [30]. The duration of
the intervention differed from a single dose to 28 days.
The length of follow-up ranged from 10 to 90 days.
Outcomes
Among the outcome variables, most of the significant dif-
ferences between the test and control groups were in
inflammatory parameters, suggesting attenuation of SIRS,
CARS, or both (Table 3). Only monoclonal antibodies
against CD18 [23] exacerbated SIRS and hypertonic saline
with dextran had a mixed effect on CARS [27]. Significant
changes in infection and mortality rates were only mea-
sured in the studies testing IFN-g [18,26], immunoglobulin
[20,32], and glucan [29,30]. These were not the most
recently published or largest studies, nor the studies with
Table 1 Quality assessment
Study Patients
randomized
Groups similar
at baseline
Groups
treated
equally
All patients
accounted for
Assessor blinded
or objective
Intention to
treat analysis
TOTAL
(max 6)
Level of
Evidence
Browder et al,
1990 [29]
11 1 1 1 1 6 1 b
Bulger et al,
2008 [19]
11 1 1 1 1 6 1 b
Croce et al,
1998 [24]
10 ° 1 1 1 1 5 2 b
de Felippe
et al, 1993 [30]
11 1 1 1 0 5 2 b
Douzinas et al,
2000 [32]
10 * 1 1 1 0 4 2 b
Dries et al,
1998 [18]
11 1 1 1 0 5 2 b
Glinz et al,
1985 [20]
11 1 1 1 1 6 1 b
Livingston et al,
1994 [31]
11 1 1 1 1 6 1 b
Marzi et al,
1993 [25]
11 1 1 1 1 6 1 b
Miller & Lim,
1985 [14]
1 n.r. 1 1 1 0 4 2b
Nakos et al,
2002 [26]
11 1 1 1 1 6 1 b
Nathens et al,
2006 [21]
11 1 1 1 1 6 1 b
Polk et al,
1992 [22]
10 ° 1 1 1 1 5 2 b
Rhee et al,
2000 [23]
10 1 1 1 1 5 2 b
Rizoli et al,
2006 [27]
10 1 1 1 0 4 2 b
Seekamp et al,
2004 [16]
11 1 1 1 1 6 1 b
Vassar et al,
1991 [15]
11 1 1 1 1 6 1 b
Waydhas et al,
1998 [28]
11 1 1 1 0 5 2 b
1 = yes; 0 = no; n.r. = not reported, the test group was older; * = the test group had a higher injury severity score, which was corrected for using a multiple
regression model.
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Study Patients Intervention
n Age
(range)
ISS (range,
± SD)
Test Control Delivery Initiation Duration Length
of
follow-
up
Browder
et al, 1990
[29]
38 34 (18-65) 24 (8-41) Glucan placebo (saline) i.v. after exploratory
laparotomy or
thoracotomy
7 days 10 days
Bulger
et al, 2008
[19]
209 38 (13-90) 28 (0-75) Hypertonic saline +
Dextran
Lactated Ringer
solution
i.v. initial reperfusion
fluid
single dose 28 days
Croce et al,
1998 [24]
16 32 (15-75) 29 Partial liquid
ventilation with
perflubron
Conventional
mechanical
ventilation
Inhaled day of admission 4 days hospital
discharge
de Felippe
et al, 1993
[30]
41 35 (16-76) n.r.* Glucan placebo i.v. 12-145 hr (mean
46.2 hr) after
admission
3-17 days hospital
discharge
Douzinas
et al, 2000
[32]
39 32 24 (16-50) Immunoglobulin placebo (albumin) i.v. 12 hr after
admission
6 days hospital
discharge
Dries et al,
1998 [18]
73 31 34 (21-59) rhIFN-g placebo s.c. within 30 hr of
injury
21 days or
hospital
discharge
60 days
Glinz et al,
1985 [20]
150 39 (15-78) 30 (9-66) Immunoglobulin placebo (albumin) i.v. within 24 hr of
starting mechanical
ventilation
12 days 42 days
Livingston
et al, 1994
[31]
98 30 (>16) 30 (±8) rhIFN-g placebo s.c. day of admission 10 days 30 days
Marzi et al,
1993 [25]
24 32 (18-57) 34 (27-57) superoxide
dismutase
placebo (sucrose) i.v. within 48 hr of
injury
5 days 14 days
Miller &
Lim, 1985
[14]
28 n.r. >10 Dextran + standard
treatment
standard treatment i.v. within 12 hr of
admission
5 days 4 weeks
Nakos
et al, 2002
[26]
21 49 (35-67) 41 (24-62) rhIFN-g placebo inhaled 2nd or 3rd day
after admission
7 days hospital
discharge
Nathens
et al, 2006
[21]
268 42 (>17) 24 (±11) Leukoreduced (<5 ×
10^6 WBC) RBC
transfusion
Nonleukoreduced (5
× 10^9WBC) RBC
transfusion
i.v. within 24 hr of
injury
28 days 28 days
Polk et al,
1992 [22]
193 32 (>15) 33 (>20) rhIFN-g placebo s.c. day of admission 10 days 90 days
Rhee et al,
2000 [23]
116 40 (>18) 20 (±11) rhMAbCD18 placebo i.v. day of admission single dose hospital
discharge
Rizoli et al,
2006 [27]
24 48 (>16) 26 (±11) Hypertonic saline +
Dextran
placebo (saline) i.v. upon arrival in de
emergency
department
single dose hospital
discharge
Seekamp
et al, 2004
[16]
84 36 (17-72) 32 (17-59) Anti-L-Selectin
(Aselizumab)
placebo i.v. within 6 hr of injury single dose 42 days
Vassar
et al, 1991
[15]
48 36 31 (±3) Prostaglandin E1 placebo i.v. 24-48 hr after
hospital admission
7 days hospital
discharge
Waydhas
et al, 1998
[28]
40 33 (18-70) 41 (±13) Antithrombin III placebo (albumin) i.v. within 6 hr of injury 4 days hospital
discharge
IFN, interferon; ISS, injury severity score; i.v., intravenous; n, number; n.r., not reported; RBC, red blood cell; s.c., subcutaneous; WBC, white blood cell; * Trauma
score 10, denoted as ‘severe multiple trauma’.
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Infection MOF, Mortality Inflammation
Test
intervention
Study Test group (relative to
control)
Effect Test group
(relative to
control)
Effect Test group (relative to
control)
Effect
Reduce
immune
paralysis
Plasma
expander
Miller &
Lim, 1985
[14]
Mortality 0 vs
0 n.s.
No
effect
immune reactive capacity n.s. No
effect
Rizoli et al,
2006 [27]
pneumonia
0.5% vs 0.5% n.s.
No
effect
Mortality 0 vs
14.3% n.s., MOF
score 1.68 vs 1.9
n.s.
No
effect
WBC n.s.; decreased toward
normal: CD11b, CD62L, CD16,
and TNFa; increased toward
normal: CD14, IL-1RA, and IL-10
all P < 0.05
SIRS↓
and
CARS↓↑
Bulger
et al, 2008
[19]
nosocomial infections
18.2% vs 15.2% n.s.
No
effect
ARDS-free survival,
MOF, mortality
29.1% vs 22.2% n.
s.
No
effect
Immuno-
globulin
Glinz et al,
1985 [20]
any 47% vs 68% P =
0.02, pneumonia 37% vs
58% P = 0.01, sepsis 18%
vs 26% n.s.
↓ Mortality from
infection* 12% vs
11% n.s.
No
effect
acute phase proteins n.s. No
effect
Douzinas
et al, 2000
[32]
pneumonia 10% vs 61%
P = 0.003
↓ Mortality rom
infection* 0 vs 0
No
effect
C3 and CH50 n.s., C4 increased
p = 0.04, increased serum
bactericidal activity P <
0.000001
CARS↓
IFN- g Polk et al,
1992 [22]
major 39% vs 35%,
minor 20% vs 28%,
pneumonia 27% vs 24%
n.s.
No
effect
Mortality 9.2% vs
12.5% n.s.
No
effect
HLA-DR increased P = 0.0001 CARS↓
Livingston
et al, 1994
[31]
major infection 48% vs
31% n.s.
No
effect
WBC decreased P < 0.05, HLA-
DR increased P < 0.05
SIRS↓
and
CARS↓
Dries et al,
1998 [18]
major infection 49% vs
58% n.s.
No
effect
Mortality 13% vs
42% P = 0.017
↓ TNFa, IL-1b, IL-2, IL-4, IL-6 n.s. No
effect
Nakos et
al, 2002
[26]
ventilator-associated
pneumonia 9% vs 50%
p < 0.05
↓ Mortality 27% vs
40% n.s.
No
effect
HLA-DR expression, IL-1b,
phospholipase A2 all increasedP
< 0.05; total cells in BAL and IL-
10 decreased P < 0.01
SIRS↓
and
CARS↓
Glucan Browder
et al, 1990
[29]
sepsis 9.5% vs 49% P <
0.05
↓ Mortality from
sepsis* 0 vs 18%
n.s.
No
effect
IL-1b decreased P < 0.05, TNFa
n.s.
SIRS↓
de Felippe
et al, 1993
[30]
pneumonia 9.5% vs 55%
P < 0.01, sepsis 9.9% vs
35% P < 0.05, either or
both 14.3% vs 65% P <
0.001
↓ Mortality: general
23.5% vs 42.1%,
related to
infection 4.8% vs
30% P < 0.05
↓
Reduce
hyper
inflammation
Superoxide
dismutase
Marzi et al,
1993 [25]
Mortality 17% vs
8.3% n.s. MOF
score n.s.
No
effect
WBC count, CRP, PMN-elastase
and IL-6 n.s.; phospholipase A2
and conjugated dienes
decreased P < 0.05
SIRS↓
Antithrombin
III
Waydhas
et al, 1998
[28]
Mortality 15% vs
5%, MOF 20% vs
30% n.s
No
effect
soluble TNF receptor II,
neutrophil elastase, IL-RA, IL-6,
and IL-8 n.s.
No
effect
Anti-CD18 Rhee et al,
2000 [23]
major and minor 38% vs
40% n.s.
No
effect
Mortality 5.8% vs
6.7%, MOF score
n.s.
No
effect
WBC increased P-value not
reported
SIRS↑
Anti-L-Selectin Seekamp
et al, 2004
[16]
67% vs 55% n.s. No
effect
MOF n.s., mortality
11% vs 25% n.s.
No
effect
WBC, IL-6, IL-10, neutrophil
elastase, C3a, procalcitonin n.s.
No
effect
Leukoreduced
blood
Nathens et
al, 2006
[21]
30% vs 36% n.s. No
effect
Mortality 19% vs
15% n.s. MOF
score 6.6 vs
5.9 n.s.
No
effect
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studies regarding the ages or ISS of the patients. Besides
the test intervention, only the duration of the test inter-
vention distinguished the studies that reported a signifi-
cant efficacy in preventing adverse clinical outcome from
those that did not; none of the single-dose interventions
proved efficacious [16,17,19,23,27].
Discussion
Although posttraumatic immune deregulation is appar-
ent, the solution is not. In this systematic review we
show that administration of immunomodulative inter-
ventions often leads to beneficial changes in the inflam-
matory response. Only administration of
immunoglobulin, IFN-g, or glucan was efficacious in
reducing infection and/or mortality rate.
Immunoglobulin and IFN-g both increase the antigen-
presenting capacity of the host. After injury, circulating
IgG levels are decreased [32]. Administration of exogen-
ous immunoglobulins results in normalization of IgG
concentrations and thus increases IgG-mediated antigen
presentation. IgG is a plasma product obtained from
healthy donors. IgG was given in the mentioned studies
at a dose of 0.25 to 1.0 g/kg intravenously and reduced
infections in trauma patients, which was more clearly
seen in combination with antibiotics [20,32]. IFN-g
increases antigen presentation to lymphocytes via induc-
tion of HLA-DR expression on monocytes. Recombinant
IFN-g was given daily at a dose of 100 μgs u b c u t a -
neously [18,22,26,31], but only had an positive effect on
mortality [18] and infection [26] in two of four studies.
Glucan, a component of the inner cell wall of Saccharo-
mycces cerevisiae, reduces the immune paralysis via a
different manner. It decreases prostaglandin release by
macrophages but also stimulates bone marrow prolifera-
tion [29]. This bone marrow proliferation may be in
favor in the late immune paralysis. Glucan was given at
ad o s eo f5 0m g / m
2 daily [29] or 30 mg every 12 hours
[30], resulting in a reduced infection and mortality rate.
All these seemingly effective interventions started on the
day of admission and were continued until at least three
to seven days after trauma.
As every systematic review, this study has its restric-
tions. A clear limitation of the trials is their relatively
small sample size and the heterogeneity of interventions
and study populations. Furthermore, we can not com-
pletely rule out publication bias. Yet, none of the studies
report financial support by a pharmaceutical company
and some studies show a negative result. Also, no other
studies with immunoglobulin, IFN-g,o rg l u c a ni n
trauma patients were found searching the clinical trial
register database [33].
Challenges unique to the trauma population impede
designing large RCTs. Polk et al. [22] note that patient
homogeneity is difficult to achieve in multicenter trials
because different centers tend to receive different
patients. In addition, in the rush of the emergency care
of severely injured patients, informed consent must wait
until a family member is contacted [23] whereas the
initiation of treatment cannot wait. Bulger et al. [19],
Nathens et al. [21], and Rizoli et al. [27] solved this pro-
blem by gaining permission from their ethics commit-
tees to delay informed consent until after the initial
treatment, but this approach is not always accepted.
Furthermore, assessing patient eligibility for inclusion in
the trial is time consuming. Delay to randomize patients
can be avoided by using simple inclusion criteria.
Nathens et al. [21] used only one criterion, the request
of the physician for red blood cells for an expected
transfusion, but were then faced with the possible dilu-
tion of treatment effect when they performed an inten-
tion-to-treat analysis because many randomized patients
never received any blood products.
Based on the selected studies, general conclusions
regarding the efficacy of potentially immunomodulative
interventions cannot be drawn. As explained in the
results section, the intended effects of the interventions
o nt h ei n f l a m m a t o r yr e s p o n s ed i f f e r e d .F u r t h e r m o r e ,
data from pilot studies [14,24-27] and phase II trials
[16,23,24] should be used to steer future investigations
rather than to draw definitive conclusions. Interventions
that did not have a significant effect on clinical outcome
may need to be administered earlier [25], continued
longer [16,22,25,28], or need sequential specific timing
Table 3 Study results (Continued)
Perflubron Croce
et al, 1998
[24]
pneumonia 50% vs 3
75% n.s.
No
effect
Mortality 8.3% vs
25% n.s.
No
effect
WBC, neutrophils, IL-6, and IL-10
all decreased p < 0.01; capillary
leak (BAL protein), TNFa, IL-1b,
and IL-8 n.s.
SIRS↓
Prostaglandin
E1
Vassar
et al, 1991
[15]
sepsis 28% vs 30%,
major wound inf. 65% vs
72%, n.s.
No
effect
Mortality 26% vs
28%, ARDS 13% vs
32%, MOF 30% vs
32% n.s.
No
effect
PMN superoxide production
increased toward normal P <
0.02
CARS↓
ARDS, acute respiratory distress syndrome; CARS, compensatory anti-inflammatory response syndrome; CRP, C-reactive protein; HLA, human leukocyte antigen; IL,
interleukin; MOF, multiple organ failure; n.s., not significant; PMN, polymorphnuclear; SIRS, systemic inflammatory response syndrome; TNF, tumor necrosis factor;
*, excluding deaths from cardiac arrhythmias secondary to a pulmonary embolus and myocardial infarction, intracranial pressure, and tracheostomy.
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[ 2 3 ]e x p l i c i t l yc h o s ef o ras i n g l ed o s eo fa na n t i - i n f l a m -
matory cytokine because they wanted to taper the initial
hyper-inflammatory response without compounding the
later immune paralysis. Timing is essential in accurate
modulation of the immune response after trauma. The
lack of a positive effect can be the result of wrong tim-
ing rather that to the drug itself. Consequently differ-
ences in timing between interventional drugs studied in
this systematic review may contribute to disparity in
outcome.
Besides changing timing, some authors recommended
the use of larger doses [19,28]. Waydhas et al. [28] sug-
gest that concomitant heparinization interfered with the
immunomodulative effect of antithrombin III. The use
of these drugs is inevitable in severely injured patients.
Where theoretically promising approaches did not pro-
duce the results hoped for, sufficiently powered phase
IV trails are needed.
Another impediment for drawing general conclusions
is the fact that study populations differed greatly across
the studies. For example, although Croce et al. [24]
excluded patients with injuries thought to be lethal
within 30 days of injury, others only excluded patients
when the injuries were thought to be lethal within only
one [28], two [16,20,21,23], or five [30] days. Similarly,
de Felippe et al. [30] only included patients with conco-
mitant head injury, whereas other researchers excluded
patients with major head injury [16,19,23,28] or any
head injury [14,29]. Mortality by severe head injury or
massive bleeding may mask the effect of the interven-
tional drug in an intention-to-treat trial, especially in
trials with a small sample size.
Some researchers chose to exclude patients receiving
steroids [24,25,31,32], because the efficacy of immuno-
modulative interventions is likely to be affected by
simultaneous administration of steroids and/or antibio-
tics during care-as-usual [32]. However, this approach
leads to a selection bias including patients that are more
likely to have a favorable outcome.
Patient selection is imperative. Where no significant
benefit was found for the test group as a whole, study
authors postulated more specific inclusion criteria were
necessary for future studies. For example, older patients
[19,24,26], those with more severe injuries [19,23,26],
patients needing 10 or more units of packed red blood
cells [24], and those who had a longer time from injury
to enrollment in the study [24] were more susceptible
to organ dysfunction and thus likely to benefit more
from immunomodulative intervention. Selection of
patients at risk may favor the outcome where no signifi-
cant difference was found in a broader group of
patients. Researchers suggest future study participants
be select based not only the injury severity, but also on
sepsis [28] or inflammatory parameters [16] as Nakos
et al. [26] did when they only randomized patients after
ascertaining immune paralysis by measuring the HLA-
DR in bronchoalveolar lavage.
Interpretations of the efficacy of immune modulating
therapies in trauma patients remains difficult. More stu-
dies with similar study populations will aid comparison
of the effect of different interventions in trauma
patients.
Conclusions
An array of potentially immunomodulative interventions
have been tested in a heterogeneous group of trauma
patients in level 1b and 2b RCTs. Reported changes in
inflammatory parameters could indicate an attenuation
of SIRS and/or CARS; however, they were not consis-
tently accompanied by significant changes in infection
and mortality rates. Administation of immunoglobulin,
IFN-g, and glucan was efficacious whereas none of the
single-dose interventions were. Further trials powered to
measure efficacy may reveal which immunomodulative
interventions should be routinely implemented to save
lives of trauma patients.
Key messages
￿ Inflammatory complications, such as MOF and severe
infection, are the most common cause of late death in
trauma patients.
￿ An array of potentially immunomodulative interven-
tions have been tested in a heterogeneous group of
trauma patients in RCTs.
￿ Extensive disparity in study populations impairs
inter-trial evaluation of efficacy of different (immuno-
modulative) interventions. Therefore, more standardized
inclusion criteria are recommended.
￿ In most studies, the inflammatory parameters dif-
fered significantly between the test and control groups.
However, significant changes in infection, MOF, and
mortality rates were only measured in studies testing
immunoglobulin, IFN-g, and glucan.
￿ A recommendation can be made to administer
immunoglobulin, IFN-g or glucan to improve the out-
come of trauma patients.
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